Monika Engelhardt

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 655 citations · Full text

Strength and muscle mass loss with aging process. Age and strength loss

Karsten Keller, Monika Engelhardt · Muscles Ligaments and Tendons Journal · 2019 · 490 citations · Full text

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Evangelos Terpos, Martina Kleber, Monika Engelhardt et al. · Haematologica · 2015 · 391 citations · Full text

Bone Disease, Hematological Malignancy, Zoledronic Acid +14

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Essential role of stromally induced hedgehog signaling in B-cell malignancies

Christine Dierks, Jovana Grbic, Katja Zirlik et al. · Nature Medicine · 2007 · 321 citations

Tumor Biology, Signaling Pathway, Essential Role +10